Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) with specific molecular pathogenesis and prognosis, which is rare in individuals with acquired immunodeficiency syndrome (AIDS). Due to its rarity and complexity, patients of AIDS complicated with APL usually require individualized and precise treatment strategies. This paper reported a case of AIDS combined with APL. The patient received therapy consisting of lamivudine, efavirenz, tenofovir, and arsenic trioxide (ATO) 10 mg·d^-1 combined with oral all-trans retinoic acid (ATRA) 60 mg·d^-1. After the induction therapy, bone marrow reexamination showed complete response.

1.Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study[J]. Lancet HIV, 2018, 5(11): e647-e655. DOI: 10.1016/s2352-3018(18)30179-6.

2.Li XL, Li M, Wang LZ, et al. Acute promyelocytic leukemia with additional chromosome abnormalities in a patient positive for HIV: a case report and literature review[J]. Oncol Lett, 2024, 27(6): 274. DOI: 10.3892/ol.2024.14407.

3.Carroll V, Garzino-Demo A. HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape[J]. Pathog Dis, 2015, 73(7): ftv044. DOI: 10.1093/femspd/ftv044.

4.Naseem S, Murgai P, Varma N, et al. Acute myeloid leukemia presenting in a human immunodeficiency virus-positive patient[J]. J Cancer Res Ther, 2022, 18(1): 297-300. DOI: 10.4103/jcrt.JCRT_992_19.

5.Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013: 382-388. DOI: 10.1182/asheducation-2013.1.382.

6.Kimani SM, Painschab MS, Horner MJ, et al. Epidemiology of haematological malignancies in people living with HIV[J]. Lancet HIV, 2020, 7(9): e641-e651. DOI: 10.1016/s2352-3018(20)30118-1.

7.Stein L, Urban MI, O'Connell D, et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004[J]. Int J Cancer, 2008, 122(10): 2260-2265. DOI: 10.1002/ijc.23391.

8.Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003[J]. Ann Intern Med, 2008, 148(10): 728-736. DOI: 10.7326/0003-4819-148-10-200805200-00005.

9.Hagiwara S, Yotsumoto M, Odawara T, et al. Non-AIDS-defining hematological malignancies in HIV-infected patients: an epidemiological study in Japan[J]. AIDS, 2013, 27(2): 279-283. DOI: 10.1097/QAD.0b013e32835a5a7a.

10.Hernández-Ramírez RU, Shiels MS, Dubrow R, et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study[J]. Lancet HIV, 2017, 4(11): e495-e504. DOI: 10.1016/S2352-3018(17)30125-X.

11.Kunitomi A, Hasegawa Y, Lmamura J, et al. Acute promyelocytic leukemia and HIV: case reports and a review of the literature[J]. Intern Med, 2019, 58(16): 2387-2391. DOI: 10.2169/internalmedicine.1662-18.

12.Gavegnano C, Savarino A, Owanikoko T, et al. Crossroads of cancer and HIV-1: pathways to a cure for HIV[J]. Front Immunol, 2019, 10: 2267. DOI: 10.3389/fimmu.2019.02267.

13.Bick AG, Popadin K, Thorball CW, et al. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV[J]. Sci Rep, 2022, 12(1): 577. DOI: 10.1038/s41598-021-04308-2.

14.Forghieri F, Nasillo V, Bettelli F, et al. Acute myeloid leukemia in patients living with HIV infection: several questions, fewer answers[J]. Int J Mol Sci, 2020, 21(3): 1081. DOI: 10.3390/ijms21031081.

15.Kaner JD, Thibaud S, Jasra S, et al. HIV portends a poor prognosis in myelodysplastic syndromes[J]. Leuk Lymphoma, 2019, 60(14): 3529-3535. DOI: 10.1080/10428194.2019.1633631.

16.Durandt C, Potgieter JC, Mellet J, et al. HIV and haematopoiesis[J]. S Afr Med J, 2019, 109(8b): 40-45. DOI: 10.7196/SAMJ.2019.v109i8b.13829.

17.Bisetegn H, Ebrahim H. The prevalence of thrombocytopenia and leucopenia among people living with HIV/AIDS in Ethiopia: a systematic review and meta-analysis[J]. PLoS One, 2021, 16(9): e0257630. DOI: 10.1371/journal.pone.0257630.

18.Vaughan JL, Wiggill TM, Alli N, et al. The prevalence of HIV seropositivity and associated cytopenias in full blood counts processed at an academic laboratory in Soweto, South Africa[J]. S Afr Med J, 2017, 107(3): 264-269. DOI: 10.7196/SAMJ.2017.v107i3.11206.

19.Bijoy S, Bijoy S, Atluri S, et al. Acute myeloid leukemia in a patient with human immunodeficiency virus-related high-risk myelodysplastic syndrome[J]. Cureus, 2022, 14(12): e32409. DOI: 10.7759/cureus.32409.

20.Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia[J]. Leukemia, 2018, 32(6): 1277-1294. DOI: 10.1038/s41375-018-0139-4.

21.Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet[J]. Blood, 2019, 133(15): 1630-1643. DOI: 10.1182/blood-2019-01-894980.

22.Maeda Y, Yamaguchi T, Hijikata Y, et al. All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication[J]. Hematology, 2007, 12(3): 263-266. DOI: 10.1080/10245330701255130.

23.Yang Q, Feng F, Li P, et al. Arsenic trioxide impacts viral latency and delays viral rebound after termination of ART in chronically SIV-infected macaques[J]. Adv Sci (Weinh), 2019, 6(13): 1900319. DOI: 10.1002/advs.201900319.

24.Tinajero J, Ngo D, Puing A, et al. Treatment outcomes of acute myeloid leukemia in patients living with human immunodeficiency virus receiving antiretroviral therapy: a single-center experience[J]. Acta Haematol, 2023, 146(6): 490-495. DOI: 10.1159/000533346.

25.Noy A. Optimizing treatment of HIV-associated lymphoma[J]. Blood, 2019, 134(17): 1385-1394. DOI: 10.1182/blood-2018-01-791400.